Amylyx Pharmaceuticals, Inc. (AMLX): restructuring charge — Amylyx pulls RELYVRIO from market after Phase 3 miss, cuts 70% of staff

Amylyx Pharmaceuticals, Inc.

Voluntarily discontinues RELYVRIO/ALBRIOZA in U.S. and Canada; no new patients after today.
Workforce reduced ~70%; expects $19M in severance charges; cash runway extended into 2026.
Current patients may transition to free drug program; PHOENIX Open Label Extension ongoing.
Interim data from Phase 2 HELIOS (AMX0035 in Wolfram) due April 2024; webcast Apr 10.
AMX0114 for ALS expects to start clinical trial in 2H 2024; ORION PSP interim analysis mid-2025.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Amylyx Pharmaceuticals, Inc. announced a restructuring with charges of approximately $19 million affecting not specified (approximately 70%).

Type: restructuring
Charge: approximately $19 million
Affected area: not specified
Headcount: approximately 70%

Exact text from the filing

Plan by the end of the third quarter of 2024. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $19 million. The Company is also evaluating its inventory purchase commitments and the impact its Restructuring Plan will have on inventory obsolescence. The Company may also incur other

View on SEC.gov

28 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-086609

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.